Should You Buy Lumexa Imaging Holdings Inc (LMRI) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
13.830
1 Day change
-1.57%
52 Week Range
--
Analysis Updated At
2026/01/26
Based on the investor's long-term strategy and beginner knowledge level, Lumexa Imaging Holdings Inc (LMRI) is a good buy. Despite the lack of recent price momentum, the company's strong analyst ratings, favorable growth outlook, and secular tailwinds in the diagnostic imaging market make it a compelling long-term investment opportunity.
Technical Analysis
The stock closed at $14.4, unchanged from the previous close, with a regular market change of -2.04%. No trend data is available for further technical analysis.
Options Data
Positive Catalysts
2026/01/26 02:10:55
Strong analyst coverage with multiple 'Buy' and 'Outperform' ratings, price targets ranging from $22 to $23, and a positive growth outlook driven by secular tailwinds in imaging, new clinic openings, and demographic trends. The company is the second-largest outpatient diagnostic imaging operator in the U.S., with a focus on cost-effective and patient-friendly services.
Neutral/Negative Catalysts
2026/01/26 02:10:55
Financial growth metrics showed no year-over-year improvement, indicating potential challenges in profitability.
Financial Performance
In Q4 2024, revenue was $248.03 million, flat year-over-year. Net income was -$25.06 million, and EPS was -0.19. Gross margin improved slightly to 11.58%, but overall financial performance remains weak.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Analysts from Deutsche Bank, Barclays, Jefferies, Wells Fargo, William Blair, Raymond James, and Leerink have initiated coverage with 'Buy,' 'Overweight,' or 'Outperform' ratings. Price targets range from $22 to $23, with expectations of 8%-9% annual EBITDA growth over the next five years and a 30% increase in imaging centers by 2030.
Wall Street analysts forecast LMRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMRI is 22.71 USD with a low forecast of 22 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast LMRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LMRI is 22.71 USD with a low forecast of 22 USD and a high forecast of 23 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 14.050
Low
22
Averages
22.71
High
23
Current: 14.050
Low
22
Averages
22.71
High
23
Deutsche Bank
NULL -> Buy
initiated
$22
AI Analysis
2026-01-05
Reason
Deutsche Bank
Price Target
$22
AI Analysis
2026-01-05
initiated
NULL -> Buy
Reason
Deutsche Bank initiated coverage of Lumexa Imaging with a Buy rating and $22 price target. The firm says Lumexa is the second-largest independent diagnostic testing facility operator in the U.S. The company's growth drivers include share gains versus hospital outpatient via referral channels and direct-to-consumer marketing as well as an increasing advanced imaging mix, the analyst tells investors in a research note.
Barclays
Overweight
initiated
$23
2026-01-05
Reason
Barclays
Price Target
$23
2026-01-05
initiated
Overweight
Reason
Barclays initiated coverage of Lumexa Imaging with an Overweight rating and $23 price target. The firm likes the company's strong local market positions and accelerating new center openings. Lumexa benefits from rising demand for diagnostic imaging due to increasing chronic diseases and the shift to lower-cost care sites,the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LMRI
